Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Show full item record



Permalink

http://hdl.handle.net/10138/285174

Citation

Eskelund , C W , Albertsson-Lindblad , A , Kolstad , A , Laurell , A , Räty , R , Pedersen , L B , Geisler , C H , Jerkeman , M & Gronbaek , K 2018 , ' Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma ' , Haematologica , vol. 103 , no. 11 , pp. E541-E543 . https://doi.org/10.3324/haematol.2018.194399

Title: Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Author: Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna; Räty, Riikka; Pedersen, Lone Bredo; Geisler, Christian Hartmann; Jerkeman, Mats; Gronbaek, Kirsten
Contributor: University of Helsinki, Hematologian yksikkö
Date: 2018-10-31
Language: eng
Number of pages: 3
Belongs to series: Haematologica
ISSN: 0390-6078
URI: http://hdl.handle.net/10138/285174
Subject: HIGH-DOSE CYTARABINE
PROGNOSTIC VALUE
OPEN-LABEL
YOUNGER
TRIALS
KI-67
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
e541.full.pdf 562.4Kb PDF View/Open
haematol.2018.194399.full.pdf 1.078Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record